Cargando…

New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354

Multidrug-resistant pathogens pose a serious threat to human health. For decades, the antibiotic vancomycin has been a potent option when treating Gram-positive multidrug-resistant infections. Nonetheless, in recent decades, we have begun to see an increase in vancomycin-resistant bacteria. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Iliana E, White, Alexis, Kim, Wooseong, Mylonakis, Eleftherios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601562/
https://www.ncbi.nlm.nih.gov/pubmed/33019726
http://dx.doi.org/10.3390/antibiotics9100665
_version_ 1783603452083961856
author Escobar, Iliana E
White, Alexis
Kim, Wooseong
Mylonakis, Eleftherios
author_facet Escobar, Iliana E
White, Alexis
Kim, Wooseong
Mylonakis, Eleftherios
author_sort Escobar, Iliana E
collection PubMed
description Multidrug-resistant pathogens pose a serious threat to human health. For decades, the antibiotic vancomycin has been a potent option when treating Gram-positive multidrug-resistant infections. Nonetheless, in recent decades, we have begun to see an increase in vancomycin-resistant bacteria. Here, we show that the nuclear factor-kappa B (NF-κB) inhibitor N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (IMD0354) was identified as a positive hit through a Caenorhabditis elegans–methicillin-resistant Staphylococcus aureus (MRSA) infection screen. IMD0354 was a potent bacteriostatic drug capable of working at a minimal inhibitory concentration (MIC) as low as 0.06 µg/mL against various vancomycin-resistant strains. Interestingly, IMD0354 showed no hemolytic activity at concentrations as high as 16 µg/mL and is minimally toxic to C. elegans in vivo with 90% survival up to 64 µg/mL. In addition, we demonstrated that IMD0354′s mechanism of action at high concentrations is membrane permeabilization. Lastly, we found that IMD0354 is able to inhibit vancomycin-resistant Staphylococcus aureus (VRSA) initial cell attachment and biofilm formation at sub-MIC levels and above. Our work highlights that the NF-κB inhibitor IMD0354 has promising potential as a lead compound and an antimicrobial therapeutic candidate capable of combating multidrug-resistant bacteria.
format Online
Article
Text
id pubmed-7601562
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76015622020-11-01 New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354 Escobar, Iliana E White, Alexis Kim, Wooseong Mylonakis, Eleftherios Antibiotics (Basel) Article Multidrug-resistant pathogens pose a serious threat to human health. For decades, the antibiotic vancomycin has been a potent option when treating Gram-positive multidrug-resistant infections. Nonetheless, in recent decades, we have begun to see an increase in vancomycin-resistant bacteria. Here, we show that the nuclear factor-kappa B (NF-κB) inhibitor N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (IMD0354) was identified as a positive hit through a Caenorhabditis elegans–methicillin-resistant Staphylococcus aureus (MRSA) infection screen. IMD0354 was a potent bacteriostatic drug capable of working at a minimal inhibitory concentration (MIC) as low as 0.06 µg/mL against various vancomycin-resistant strains. Interestingly, IMD0354 showed no hemolytic activity at concentrations as high as 16 µg/mL and is minimally toxic to C. elegans in vivo with 90% survival up to 64 µg/mL. In addition, we demonstrated that IMD0354′s mechanism of action at high concentrations is membrane permeabilization. Lastly, we found that IMD0354 is able to inhibit vancomycin-resistant Staphylococcus aureus (VRSA) initial cell attachment and biofilm formation at sub-MIC levels and above. Our work highlights that the NF-κB inhibitor IMD0354 has promising potential as a lead compound and an antimicrobial therapeutic candidate capable of combating multidrug-resistant bacteria. MDPI 2020-10-01 /pmc/articles/PMC7601562/ /pubmed/33019726 http://dx.doi.org/10.3390/antibiotics9100665 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Escobar, Iliana E
White, Alexis
Kim, Wooseong
Mylonakis, Eleftherios
New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
title New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
title_full New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
title_fullStr New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
title_full_unstemmed New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
title_short New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
title_sort new antimicrobial bioactivity against multidrug-resistant gram-positive bacteria of kinase inhibitor imd0354
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601562/
https://www.ncbi.nlm.nih.gov/pubmed/33019726
http://dx.doi.org/10.3390/antibiotics9100665
work_keys_str_mv AT escobarilianae newantimicrobialbioactivityagainstmultidrugresistantgrampositivebacteriaofkinaseinhibitorimd0354
AT whitealexis newantimicrobialbioactivityagainstmultidrugresistantgrampositivebacteriaofkinaseinhibitorimd0354
AT kimwooseong newantimicrobialbioactivityagainstmultidrugresistantgrampositivebacteriaofkinaseinhibitorimd0354
AT mylonakiseleftherios newantimicrobialbioactivityagainstmultidrugresistantgrampositivebacteriaofkinaseinhibitorimd0354